These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38754451)

  • 21. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
    Tibau A; Hwang TJ; Molto C; Avorn J; Kesselheim AS
    JAMA Oncol; 2024 May; 10(5):634-641. PubMed ID: 38573645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
    Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
    Chen EY; Joshi SK; Tran A; Prasad V
    JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
    Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
    JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.
    Michaeli DT; Michaeli T
    J Clin Oncol; 2022 Dec; 40(35):4095-4106. PubMed ID: 35921606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
    Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
    Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.
    Ladanie A; Speich B; Briel M; Sclafani F; Bucher HC; Agarwal A; Ioannidis JPA; Pereira TV; Kasenda B; Hemkens LG
    J Clin Epidemiol; 2019 Oct; 114():49-59. PubMed ID: 31158450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study.
    Carlisle BG; Doussau A; Kimmelman J
    BMJ Open; 2020 Feb; 10(2):e034306. PubMed ID: 32071183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014.
    Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
    Otolaryngol Head Neck Surg; 2017 Apr; 156(4):683-692. PubMed ID: 28116974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
    Downing NS; Aminawung JA; Shah ND; Krumholz HM; Ross JS
    JAMA; 2014 Jan 22-29; 311(4):368-77. PubMed ID: 24449315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price.
    Michaeli DT; Michaeli T
    J Natl Compr Canc Netw; 2024 Apr; 22(4):. PubMed ID: 38648855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases.
    Nagai S; Ozawa K
    Invest New Drugs; 2018 Jun; 36(3):487-495. PubMed ID: 29453626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study.
    Gyawali B; Rome BN; Kesselheim AS
    BMJ; 2021 Sep; 374():n1959. PubMed ID: 34497044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
    Miller JE; Korn D; Ross JS
    BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
    Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
    Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
    Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
    PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
    Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
    J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.